NEW YORK, NY--(Marketwire - Jun 21, 2012) - Daxor Corporation (NYSE MKT: [ DXR ]) (NYSE Amex: [ DXR ]), an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzers in Temple University Hospital (TUH) and in two other hospitals. TUH is a 740-bed Philadelphia hospital and is one of the nation's premier academic medical centers and has been listed among the best in 13 specialties by US News & World Report. The other two hospitals each have more than 1,000 hospital beds. One is in the state of Minnesota and one is in the state of Florida. Both of these hospitals are interested in using the BVA-100 in treating their congestive heart failure patients. The identities of the two hospitals will be made some time after the instruments are installed.

Medicare has issued regulations which will penalize hospitals who readmit congestive heart failure patients in under 30 days. This regulation will be implemented in January 2013 and will provide a significant incentive for hospitals to optimize treatment of the congestive heart failure patients.

According to recent statistics 24.8% of congestive heart failure patients are readmitted for hospitalization within 30 days after being discharged. Treatment of congestive heart failure patients is the #1 expense for Medicare for patients over the age of 65.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at [ www.Daxor.com ].